Albert Gordon Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Albert Gordon Smith has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
J. Robinson Singleton
University of Utah Department of Neurology
8 shared publicationsJ Robinson Singleton
Department of Neurology, University of Utah, Salt Lake City, UT, USA
2 shared publications- John Robinson Singleton
Department of Neurology, University of Utah, Salt Lake City, UT
2 shared publications - Robin L. Marcus
University of Utah, Department of Physical Therapy & Athletic Training, Salt Lake City, UT, United States
2 shared publications - Amanda Catherine Peltier
Vanderbilt Autonomic Dysfunction Center Division of Clinical Pharmacology Department of Medicine Vanderbilt University Medical Center Nashville Tennessee USA
1 shared publication - Amro Maher Stino
Department of Neurology, University of Michigan, Ann Arbor, USA
1 shared publication
Latest Publications
- 1 January 2019
- Published by Elsevier
- Vol. 161, 217-240
Clinical electrophysiology of axonal polyneuropathies
- 1 January 2019
- Published by Elsevier
- Vol. 161, 217-240
Clinical electrophysiology of axonal polyneuropathies
- Top Cited PapersOpen Access
- 3 May 2017
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 8 (5) , 646-655
Peripheral neuropathy in prediabetes and the metabolic syndrome
Peripheral neuropathy is a major cause of disability worldwide. Diabetes is the most common cause of neuropathy, accounting for 50% of cases. Over half of people with diabetes develop neuropathy, and diabetic peripheral neuropathy (DPN) is a major cause of reduced quality of life due to pain, sensory loss, gait instability, fall‐related injury, and foot ulceration and amputation. Most patients with non‐diabetic neuropathy have cryptogenic sensory peripheral neuropathy (CSPN). A growing body of literature links prediabetes, obesity and metabolic syndrome to the risk of both DPN and CSPN. This association might be particularly strong in type 2 diabetes patients. There are no effective medical treatments for CSPN or DPN, and aggressive glycemic control is an effective approach to neuropathy risk reduction only in type 1 diabetes. Several studies suggest lifestyle‐based treatments that integrate dietary counseling with exercise might be a promising therapeutic approach to early DPN in type 2 diabetes and CSPN associated with prediabetes, obesity and metabolic syndrome.
- 3 May 2017
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 8 (5) , 646-655
Top Cited PapersOpen AccessPeripheral neuropathy in prediabetes and the metabolic syndrome
Peripheral neuropathy is a major cause of disability worldwide. Diabetes is the most common cause of neuropathy, accounting for 50% of cases. Over half of people with diabetes develop neuropathy, and diabetic peripheral neuropathy (DPN) is a major cause of reduced quality of life due to pain, sensory loss, gait instability, fall‐related injury, and foot ulceration and amputation. Most patients with non‐diabetic neuropathy have cryptogenic sensory peripheral neuropathy (CSPN). A growing body of literature links prediabetes, obesity and metabolic syndrome to the risk of both DPN and CSPN. This association might be particularly strong in type 2 diabetes patients. There are no effective medical treatments for CSPN or DPN, and aggressive glycemic control is an effective approach to neuropathy risk reduction only in type 1 diabetes. Several studies suggest lifestyle‐based treatments that integrate dietary counseling with exercise might be a promising therapeutic approach to early DPN in type 2 diabetes and CSPN associated with prediabetes, obesity and metabolic syndrome.
- 8 July 2016
- Published by Springer Nature in Current Geriatrics Reports
- Vol. 5 (3) , 150-159
Exercise in Type 2 Diabetic Peripheral Neuropathy
- 8 July 2016
- Published by Springer Nature in Current Geriatrics Reports
- Vol. 5 (3) , 150-159
Exercise in Type 2 Diabetic Peripheral Neuropathy
- Open Access
- 1 July 2016
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 73 (7) , 860-866
The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling adverse effect of lifesaving neurotoxic chemotherapy.1-3 Depending on the agent, 30% to 70% of people receiving neurotoxic chemotherapy develop neuropathy.4,5 The taxanes, platinums, and vinca alkaloids are the agents most commonly associated with CIPN. The risk of developing CIPN increases with both the total cumulative dose of chemotherapy and the exposure to multiple neurotoxic agents.5-8 Chemotherapy-induced peripheral neuropathy most commonly causes a length-dependent sensory-predominant axonal neuropathy, although the platinums and taxanes are unique in that the hands and feet can be affected simultaneously.5,9
- 1 July 2016
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 73 (7) , 860-866
Open AccessThe Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling adverse effect of lifesaving neurotoxic chemotherapy.1-3 Depending on the agent, 30% to 70% of people receiving neurotoxic chemotherapy develop neuropathy.4,5 The taxanes, platinums, and vinca alkaloids are the agents most commonly associated with CIPN. The risk of developing CIPN increases with both the total cumulative dose of chemotherapy and the exposure to multiple neurotoxic agents.5-8 Chemotherapy-induced peripheral neuropathy most commonly causes a length-dependent sensory-predominant axonal neuropathy, although the platinums and taxanes are unique in that the hands and feet can be affected simultaneously.5,9
- 2 December 2014
- Published by Wolters Kluwer Health in Neurology
- Vol. 83 (23) , 2104-2105
Reevaluating clinical measurement tools in therapeutic trials
- 2 December 2014
- Published by Wolters Kluwer Health in Neurology
- Vol. 83 (23) , 2104-2105
Reevaluating clinical measurement tools in therapeutic trials
- 1 July 2014
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 28 (4) , 511-516
The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy
- 1 July 2014
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 28 (4) , 511-516
The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy
- 1 January 2014
- Published by Elsevier
- Vol. 126, 109-122
Glucose intolerance, metabolic syndrome, and neuropathy
- 1 January 2014
- Published by Elsevier
- Vol. 126, 109-122
Glucose intolerance, metabolic syndrome, and neuropathy
- 1 September 2013
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 27 (5) , 436-442
Obesity and hyperlipidemia are risk factors for early diabetic neuropathy
- 1 September 2013
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 27 (5) , 436-442
Obesity and hyperlipidemia are risk factors for early diabetic neuropathy
- Open Access
- 22 March 2013
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 18 (1) , 54-58
Corneal confocal microscopy is efficient, well‐tolerated, and reproducible
In order to develop an efficient, reproducible, and well-tolerated protocol for assessing corneal innervation, 11 normal subjects underwent corneal confocal microscopy (CCM) using a Heidelberg Retinal Tomography III microscope. Five standardized locations were sampled in the left eye and one centrally in the right. The protocol was repeated 1–4 weeks later. A blinded technician measured nerve fiber length (NFL) and tortuosity coefficient (TC). The relationship between image location and NFL and TC was assessed using one-way analysis of variance, and reproducibility determined using relative intertrial variability and intraclass correlation coefficients. NFL reproducibility was maximized by averaging four or more images from the left eye, or one central image from both eyes. TC was less reproducible. CCM is a rapid, well-tolerated, and reproducible method for assessing corneal innervation.
- 22 March 2013
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 18 (1) , 54-58
Open AccessCorneal confocal microscopy is efficient, well‐tolerated, and reproducible
In order to develop an efficient, reproducible, and well-tolerated protocol for assessing corneal innervation, 11 normal subjects underwent corneal confocal microscopy (CCM) using a Heidelberg Retinal Tomography III microscope. Five standardized locations were sampled in the left eye and one centrally in the right. The protocol was repeated 1–4 weeks later. A blinded technician measured nerve fiber length (NFL) and tortuosity coefficient (TC). The relationship between image location and NFL and TC was assessed using one-way analysis of variance, and reproducibility determined using relative intertrial variability and intraclass correlation coefficients. NFL reproducibility was maximized by averaging four or more images from the left eye, or one central image from both eyes. TC was less reproducible. CCM is a rapid, well-tolerated, and reproducible method for assessing corneal innervation.
- 31 October 2012
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 26 (5) , 361-362
Exercise for diabetic neuropathy: A toe in the therapeutic door
- 31 October 2012
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 26 (5) , 361-362
Exercise for diabetic neuropathy: A toe in the therapeutic door